CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy

Tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell product targeting CD19 is approved for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the impact of pretreatment variables, such as CD19 expression level, on leukemic blasts, the presence of CD19(–) subpopulations,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Pillai, Vinodh, Muralidharan, Kavitha, Meng, Wenzhao, Bagashev, Asen, Oldridge, Derek A., Rosenthal, Jaclyn, Van Arnam, John, Melenhorst, Jos J., Mohan, Diwakar, DiNofia, Amanda M., Luo, Minjie, Cherian, Sindhu, Fromm, Jonathan R., Wertheim, Gerald, Thomas-Tikhonenko, Andrei, Paessler, Michele, June, Carl H., Luning Prak, Eline T., Bhoj, Vijay G., Grupp, Stephan A., Maude, Shannon L., Rheingold, Susan R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Immunobiology and Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6880911/
https://ncbi.nlm.nih.gov/pubmed/31738832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000692
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados